期刊文献+

接受连续性肾脏替代治疗的重症心衰患者的早期死亡影响因素分析 被引量:1

Factors Influencing Early Death in Patients with Severe Heart Failure Treated by Continuous Renal Replacement Therapy
下载PDF
导出
摘要 【目的】分析接受连续性肾脏替代治疗(CRRT)的重症心衰患者早期死亡的影响因素。【方法】观察100例接受CRRT的重症心衰患者治疗28d内病死率,根据是否死亡分为死亡组和存活组。收集患者临床病例资料并分析死亡的影响因素。【结果】100例患者中共46例患者死亡,病死率为46.0%,其中14d内病死率为34.0%(34/100)。死亡组与存活组全身炎症反应综合征(SIRS)比例、脓毒症比例、平均动脉压水平、碱剩余(BE)、急性生理与慢性健康评分(APACHEⅡ)、序贯器官衰竭估计评分(SOFA)、pH、氨基末端脑钠肽(NT-proBNP)水平、开始治疗时间、治疗后达到液体负平衡时间相比较差异有显著性(P<0.05)。多因素回归分析结果显示,SIRS、脓毒症、平均动脉压、pH、开始治疗时间、SOFA评分是患者死亡独立影响因素(P<0.05),合并SIRS、合并脓毒症、平均动脉压≤60mmHg、pH≤7.35、SOFA评分>10分的CRRT重症心衰患者预后较差。【结论】接受CRRT的重症心衰患者28d内死亡的影响因素较多,合并SIRS、合并脓毒症、平均动脉压≤60mmHg、pH≤7.35、SOFA评分>10分、开始治疗时间>24h是患者28d内死亡的危险因素。 【Objective】To analyze the factors affecting early death in patients with severe heart failure with CRRT.【Methods】A total of 100 patients with severe heart failure who underwent CRRT were enrolled.The mortality of patients treated for 28 days was observed.The patients were divided into death group and survival group according to whether they died.Patient clinical case data were collected and the influencing factors of death was analyzed.【Results】Among the 100 patients,46 patients died,with a mortality rate of 46.0%,of which 34.0%(34/100)died within 14 days.Among the death group and the survival group,there were significant differences in the proportion of systemic inflammatory response syndrome(SIRS),sepsis,mean arterial pressure,base excess(BE),acute physiology and chronic health score(APACHEⅡ),sequential organ failure assessment score(SOFA),pH,N-terminal brain natriuretic peptide(NT-proBNP)level,time to start treatment and time to reach negative fluid balance after treatment(P<0.05).Multivariate regression analysis showed that Sirs,Sepsis,mean arterial pressure,pH,start time of treatment,SOFA score were independent influencing factors of death(P<0.05).CRRT patients of severe heart failure with SIRS,Sepsis,mean arterial pressure≤60mmHg,pH≤7.35,SOFA score>10 had poor prognosis.【Conclusion】There are many influencing factors of death within 28 days in patients with severe heart failure receiving CRRT.Patients with SIRS,Sepsis,mean arterial pressure≤60mmHg,pH≤7.35,SOFA score>10,and starting treatment time>24h were risk factors for death within 28d.
作者 姬利华 卢锋 JI Li-hua;LU Feng(Department of Critical Care Medicine,Xingyuan Hospital of Yulin,Yulin Shaanxi,719000)
出处 《医学临床研究》 CAS 2021年第3期399-402,共4页 Journal of Clinical Research
关键词 心力衰竭 肾替代疗法/方法 死亡 危险因素 Heart Failure Renal Replacement Therapy/MT Death Risk Factors
  • 相关文献

参考文献4

二级参考文献29

  • 1Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagaaosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC [J]. Eur Heart J, 2016 May 20. pii: ehw128. [ Epub ahead of print].
  • 2Mebazaa A, Yilmaz MB, Levy P, et al. Recommendations on pre- hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine [ J]. Eur J Heart Fail, 2015, 17 (6) : 544-558.
  • 3McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 : The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC [J]. Eur Heart J, 2012, 33 (14): 1787- 1847.
  • 4National Clinical Guideline Centre (UK). Acute heart failure: diagnosing andmanaging acute heart failure in adults. (Clinical Guideline CG187) [ M]. London: National Institute for Health and Care Excellence ( UK), 2014.
  • 5Nohria A, Tsang SW, Fang JC, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patientsadmitted with heart failure [ J ]. J Am Coll Cardiol, 2003, 41 ( 10 ) : 1797- 1804.
  • 6Stevenson LW. Design of therapy for advanced heart failure [ J ]. EurJ Heart Fail, 2005, 7 (3): 323-331.
  • 7Thiele H, Zeymer U, Neumann FJ, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock [ J ]. N Engl J Med, 2012, 367 (14) : 1287-1296.
  • 8Thiele H, Zeymer U, Neumann FJ, et al. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II) : final 12 month results of a randomised, open-label trial [J]. Lancet, 2013, 382 (9905): 1638-1645.
  • 9Cardiology Branch of the Chinese Medical Association, Chinese Journal of Cardiology Editorial Board. Guidelines for the diagnosis and treatment of heart failure in China 2014 [J]. Chin J Cardiol, 2014, 42 (2): 98-122.
  • 10Cheng K, Xu F, Chen YG. Interpretation of 2015 European recommendations on pre-hospital & early hospital management of acute heart failure [ J ]. Chin J Emerg Med, 2015, 24 ( 7 ) : 697 -700.

共引文献97

同被引文献9

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部